PDGFRα-positive cell-derived TIMP-1 modulates adaptive immune responses to influenza A viral infection

Our data strongly link tissue inhibitor of metalloproteinases-1 (TIMP-1) to influenza A virus (IAV) pathogenesis. TIMP-1 is highly increased in PDGFRα-lineage cells during IAV infection. Transforming growth factor-β (TGF-β) induces TIMP-1 during lipofibroblast (lipoFB)-to- myofibroblast (myoFB) tran...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Lung cellular and molecular physiology Vol. 328; no. 1; pp. L60 - L74
Main Authors Dutta, Saugata, Zhu, Yin, Almuntashiri, Sultan, Peh, Hong Yong, Zuñiga, Joaquin, Zhang, Duo, Somanath, Payaningal R., Ramírez, Gustavo, Irineo-Moreno, Valeria, Jiménez-Juárez, Fabiola, López-Salinas, Karen, Regino, Nora, Campero, Paloma, Crocker, Stephen J., Owen, Caroline A., Wang, Xiaoyun
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.01.2025
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Our data strongly link tissue inhibitor of metalloproteinases-1 (TIMP-1) to influenza A virus (IAV) pathogenesis. TIMP-1 is highly increased in PDGFRα-lineage cells during IAV infection. Transforming growth factor-β (TGF-β) induces TIMP-1 during lipofibroblast (lipoFB)-to- myofibroblast (myoFB) transdifferentiation. Timp-1 deficiency protects mice from H1N1 IAV-induced weight loss, mortality, and lung injury. TIMP-1 may be a novel therapeutic target for IAV infection. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a physiologic inhibitor of the matrix metalloproteinases (MMPs), but little is known about the role of TIMP-1 in regulating the pathogenesis of influenza A virus (IAV) infection. Here, we performed both in vivo and in vitro experiments to investigate the regulation and function of TIMP-1 during IAV infection. Specifically, plasma levels of TIMP-1 are significantly increased in human subjects and wild-type (WT) mice infected with 2009 H1N1 IAV compared with levels in uninfected controls. Also, TIMP-1 is strikingly upregulated in PDGFRα positive (PDGFRα + ) cells in IAV-infected murine lungs as demonstrated using conditional KO (cKO) mice with a specific deletion of Timp-1 in PDGFRα + cells. Our in vitro data indicated that TIMP-1 is induced by transforming growth factor-β (TGF-β) during lipofibroblasts (lipoFBs)-to-myofibroblast (myoFB) transdifferentiation. Timp-1 deficiency protects mice from H1N1 IAV-induced weight loss, mortality, and lung injury. IAV-infected Timp-1-deficient mice showed increased macrophages, and B and T cell counts in bronchoalveolar lavage (BAL) on day 7 postinfection (p.i.), but reduced BAL neutrophil counts. Increased Cxcl12 levels were detected in both BAL cells and lungs from Timp-1-deficient mice on day 3 p.i. Taken together, our data strongly link TIMP-1 to IAV pathogenesis. We identified that PDGFRα-lineage cells are the main cellular source of elevated TIMP-1 during IAV infection. Loss of Timp-1 attenuates IAV-induced mortality and promotes T and B cell recruitment. Thus, TIMP-1 may be a novel therapeutic target for IAV infection. NEW & NOTEWORTHY Our data strongly link tissue inhibitor of metalloproteinases-1 (TIMP-1) to influenza A virus (IAV) pathogenesis. TIMP-1 is highly increased in PDGFRα-lineage cells during IAV infection. Transforming growth factor-β (TGF-β) induces TIMP-1 during lipofibroblast (lipoFB)-to- myofibroblast (myoFB) transdifferentiation. Timp-1 deficiency protects mice from H1N1 IAV-induced weight loss, mortality, and lung injury. TIMP-1 may be a novel therapeutic target for IAV infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
CAO and XW conceived the project and designed experimental protocols. SA, SD, YZ, HYP, DZ, and XW acquired data and analyzed and interpreted results. SJC provided a novel transgenic mouse model and reviewed the manuscript. PRS contributed to the experimental ideas and reviewed the manuscript. JZ, GR, VI, FJ, KL, NR, and PC provided samples and clinical information. SA, SD, DZ, and XW wrote the manuscript. All authors reviewed and approved the manuscript.
AUTHOR CONTRIBUTIONS
S. Dutta, Y. Zhu, and S. Almuntashiri contributed equally to this work
ISSN:1040-0605
1522-1504
1522-1504
DOI:10.1152/ajplung.00104.2024